MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-010248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Meiou Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunotherapy, Adoptive, Neoplasm Proteins, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency (JST) SPRING, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
The development of chimeric antigen receptor (CAR)-T cell therapies for solid tumors has attracted considerable attention, yet their clinical efficacy remains limited. Therefore, various efforts have been made to improve the efficacy of CAR-T cell therapy. As one promising strategy, incorporating the T-cell receptor (TCR) machinery into CAR structures has been reported to improve the efficacy of CAR-T cells in studies using conventional CARs targeting such as EGFR. However, in the case of peptide/major histocompatibility complex (pMHC)-targeted CARs, the advantages of exploiting TCR machinery have not been fully elucidated. We recently developed MAGE-A4-derived pMHC (MAGE-A4 pMHC)-targeted CAR-T cells (MA-CAR-T cells) using a highly specific human scFv antibody against MAGE-A4 p230-239 /HLA-A*02:01. We aimed to determine whether MAGE-A4 pMHC-targeted CAR-T cells using the TCR machinery (Hybrid MA-TCR-T cells) exhibit superior functionality without compromising antigen specificity.
Methods
We constructed a retroviral vector expressing Hybrid MA-TCR where MAGE-A4 pMHC-specific scFv are fused to human TCR constant chains.
Results
Hybrid MA-TCR-T cells demonstrated superior in vitro functions compared with MA-CAR-T cells, while maintaining strict antigen specificity. In addition, functional superiority of Hybrid MA-TCR-T cells to MA-CAR-T cells became more pronounced on repetitive antigen stimulation. In particular, Hybrid MA-TCR-T cells significantly inhibited tumor growth in an immunodeficient mouse model more effectively than MA-CAR-T cells. Ex vivo analyses indicated that their enhanced therapeutic efficacy might result from higher infiltration of functionally active, less differentiated Hybrid MA-TCR-T cells in tumor tissues.
Conclusions
These findings suggest that leveraging the TCR machinery is a promising strategy for enhancing pMHC-targeted CAR-T cell therapy for solid tumors, potentially leading to more effective treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
- Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
- Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan miyahr-y@med.mie-u.ac.jp.
ORCID-Profile: Meiou Liu, Yasushi Akahori, Naoko Imai, Linan Wang, Kohei Negishi, Takuma Kato, Hiroshi Fujiwara, Hiroshi Miwa, Yoshihiro Miyahara
Förderung
- Japan Science and Technology Agency (JST) SPRING
- Japan Agency for Medical Research and Development
Zitieren
APA
Liu, M., Akahori, Y., Imai, N., Wang, L., Negishi, K., Kato, T., Fujiwara, H., Miwa, H., Shiku, H., & Miyahara, Y. (2024). MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010248
Vancouver
Liu M, Akahori Y, Imai N, Wang L, Negishi K, Kato T, et al. MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-010248
BibTeX
@article{Liu2024,
author = {Liu, Meiou and Akahori, Yasushi and Imai, Naoko and Wang, Linan and Negishi, Kohei and Kato, Takuma and Fujiwara, Hiroshi and Miwa, Hiroshi and Shiku, Hiroshi and Miyahara, Yoshihiro},
title = {MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-010248}
}
EUVIMED